Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis

Autoimmunity Reviews

Volumn 11, Issue 11, 2012, Pages 827-835

  Martin, Patricia ^a   Teodoro, Walcy R ^a   Velosa, Ana Paula P ^a   de Morais, Jymenez ^a   Carrasco, Solange ^a   Christmann, Romy B ^b   Goldenstein Schainberg, Cláudia ^a   Parra, Edwin R ^a   Katayama, Maria Lúcia ^a   Sotto, Mirian N ^a   Capelozzi, Vera L ^a   Yoshinari, Natalino H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Modified Rodnan Skin Score; Skin; Systemic sclerosis; Type V collagen; Valentini Disease Activity Index

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 5;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; MORPHOMETRICS; PROTEIN STRUCTURE; REVIEW; SKIN BIOPSY; SKINFOLD; SYSTEMIC SCLEROSIS;

ADULT; BIOPSY; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE V; DERMIS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

EID: 84865356287     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.02.017     Document Type: Review

References (49)

1. Derk C.T., Jimenez S.A. Systemic sclerosis. Current views of its pathogenesis. Autoimmunity Rev 2003, 2:181-191.
2. Quinones F., Crouch E. Biosynthesis of interstitial and basement membrane collagens in pulmonary fibrosis. Am Rev Resp Dis 1986, 134:1163-1171.
3. Gelse K., Poschl E., Aigner T. Collagens: strutcture, function and byosynthesis. Adv Drug Deliv Rev 2003, 55:1531-1546.
4. Birk D.E., Fitch J.M., Babiarz J.P., Doane K.J., Linsenmayer T.F. Collagen fibrillogenesis in vitro: interaction of types I and V collagen regulates fibril diameter. J Cell Sci 1990, 95:649-657.
5. Birk D.E. Type V collagen: heterotipic type I/V collagen interactions in the regulation of fibril assembly. Micron 2001, 32:223-237.
6. Chanut-Delalande H., Bonod-Bidaud C., Cogne S., Malboyres M., Ramirez F.., Fichard A., et al. Development of a functional skin matrix requires deposition of collagen V heterotrimers. Mol Cell Biol 2004, 24:6049-6057.
7. Roulet M., Ruggiero F., Karsenty G., LeGuellec D. A comprehensive study of the spatial and temporal expression of the col5a1 gene in mouse embryos: a clue for understanding collagen V function in developing connective tissues. Cell Tissue Res 2007, 327:323-332.
8. Parra E.R., Aguiar A.C., Teodoro W.R., de Souza R., Yoshinari N.H., Capelozzi V.L. Collagen V and vascular injury promote lung architectural changes in systemic sclerosis. Clin Respir J 2009, 3:135-142.
9. Parra E.R., Teodoro W.R., de Morais J., Katayama M.L., de Souza R., Yoshinari N.H., et al. Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis. Eur J Clin Invest 2010, 40:110-120.
10. Teodoro W.R., Velosa A.P.P., Witzel S.S., Garippo A.L., Farhat C., Parra E..R, et al. Architectural remodeling in lungs of rabbits induced by type V collagen immunization: a preliminary morphologic model to study diffuse connective tissue diseases. Pathol Res Pract 2004, 200:681-691.
11. Bezerra M.C., Teodoro W.R., de Oliveira C.C., Velosa A.P., Ogido L.T., Gauditano T., et al. Scleroderma like remodeling induced by type V collagen. Arch Dermatol Res 2006, 298:51-57.
12. Marangoni R.G., Parra E.R., Barbeiro H.V., Velosa A.P.P., Soriano V.G., Teodoro W.R., et al. Experimental model of systemic sclerosis induced by collagen V reproduces extra and intrapulmonary artery disfunction (Abstract). Clin Exp Rheumatol 2010, 5(62):31. Suppl.
13. Callado M.R., Viana V.S., Vendramini M.B., Leon E.T., Bueno C., Velosa A.P., et al. Autoantibody profile in the experimental model of scleroderma induced by type V human collagen. Immunology 2007, 122:38-46.
14. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (Scleroderma). Arthritis Rheum 1980, 23:581-592.
15. White B., Bauer E.A., Goldsmith L.A., Hochberg M.C., Katz L.M., Korn J.H., et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-Modification Intervention. Arthritis Rheum 1995, 38:351-360.
16. Clements P.J., Lachenbruch P., Seibold J. Inter and Intraobsever variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
17. Valentini G., Silman A.J., Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003, 21(Suppl.):S39-S41.
18. Cotton S.A., Herrick A.L., Jaysson M.I.V., Freemont A. Endothelial expression of nitric oxide synthases and nitrotyrosin in systemic sclerosis skin. J Pathol 1999, 189:273-278.
19. Spiess K., Teodoro W.R., Zorn T.M.T. Distribution of collagen types I, III and V in pregnant mouse endometrium. Conective Tissue Res 2007, 48:99-108.
20. Sorrel M.J., Baber M.M., Caplan A.J. Site matched papilary and reticular dermal fibroblasts difer in their release of specific growth factores, cytokines and their interaction with keratinocytes. J Cell Pathol 2004, 200:134-145.
21. Coelho J.C., Giugliane R. Fibroblasts of skin fragments as a tool for the investigation of genetic diseases: technical recommendations. Genet Mol Biol 2000, 23:269-271.
22. Pannu J., Gardner H., Shearstone J.R., Smith E., Trojanowska M. Increased levels of transforming growth factor beta receptor type I and up regulation of matrix gene program. Arthritis Rheum 2006, 54:3011-3021.
23. Livak N.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta-Delta C(T)] method. Methods 2001, 25:402-408.
24. Souza P., Rizzardi F., Noleto G., Atanazio M, Bianchi O., Parra E.R., et al. Refractory remodeling of the microenvironment by abnormal type V collagen, apoptosis, and immune response in non-small cell lung cancer. Hum Pathol 2010, 41:239-248.
25. Gao M.Q., Kim G.B., Kang S., Choi P.Y., Park H., Kang K.S., et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci 2010, 123:3507-3514.
26. Behr J., Furst D.E. Pulmonary function tests. Rheumatology 2008, 47:v65-v67.
27. Wells A.U. High-resolution computed tomography and scleroderma lung disease. Rheumatology 2008, 47:v59-v61.
28. Fleischmajer R., Gay S., Meigel W.N., Perlish J. Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 1978, 21:418-427.
29. Liu T., Zhang J. Detection of V, III and I type collagens of dermal tissues in skin lesions of patients with systemic sclerosis and its implication, J. Huazhong. Univ Sci Technol Med Sci 2008, 28:599-603.
30. Corriveau M.P., Noufaied I., Lessard J. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstruction of skin fibrosis development using a tissue engineering aproach. J Pathol 2009, 217:534-542.
31. Wigley F.M., Hummers L.K. Clinical features of systemic sclerosis. Rheumatology 2003, 1463-1479. Elsevier Limited, London. M.C. Hochberg, A.J. Silman, J.S. Smolen, M. Weinblatt, M. Weisman (Eds.).
32. Malfait F., Wenstrup R.J., de Paepe A. Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. Genet Med 2010, 12:597-605.
33. Sargent J.L., Milano A., Bhattachayya S., Varga J., Connoly M.K., Chang H.Y., et al. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010, 130:694-705.
34. Brinckmann J., Kim S., Wu J., Reinhardt D.P., Batmunkh C., Metzen E., et al. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysil hidroxylase 2 and an altered cross link pattern: important pathogenetic steps in early and late stage of systemic scleroderma. Matrix Biol 2005, 24:459-468.
35. Henkel W., Dreisewerd K. Cyanogen bromide peptides of the fibrillar collagens I, III, and V and their mass spectrometric characterization: detection of linear peptides, peptide glycosylation, and cross-linking peptides involved in formation of homo- and heterotypic fibrils. J Proteome Res 2007, 6:4269-4289.
36. Sakkas L.I., Platsoucas C.D. Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum 2004, 50:1721-1733.
37. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., Platsoucas C.D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
38. Haque M.A., Mizobuchi T., Yasufuku K., Fujisawa T., Brutkiewicks R.R., Zeng Y., et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002, 169:1542-1549.
39. Bharat A., Fields R.C., Steward N., Trulock E.P., Patterson G.A., Mohanakumar T. CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant 2006, 6:1799-1808.
40. Jaramillo A., Smith M.A., Phelan D., Sundaresan S., Trulock E.P., Lynch J.P., et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999, 67:1155-1161.
41. Yasufuku K., Heidler K.M., O'Donnell P.W., Smith G.N., Cummings O.W., Foresman B.H., et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 2001, 25:26-34.
42. Yasufuku K., Heidler K.M., Woods K.A., Smith G.N., Cummings O.W., Fujisawa T., et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002, 73:500-505.
43. Velosa A.P.P., Teodoro W.R., Oliveira C.C., Dos Santos Filho A., Moutinho R.F., Santos A.G., et al. Collagen V nasal tolerance in experimental model of systemic sclerosis. Arch Dermatol Res 2007, 229:177-189.
44. Velosa A.P.P., Teodoro W.R., dos Anjos D.M., Konno R., Oliveira C.C., Katayama M.L., et al. Collagen V-induced nasal tolerance downregulates pulmonary collagen mRNA gene and TGF-beta expression in experimental systemic sclerosis. Respir Res 2010, 11:1-10.
45. Riente L., Marchini B., Dolcher M.P., Puccetti A., Bombardieri S., Migliorini P. Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon. Clin Exp Immunol 1995, 102:354-359.
46. Luparello C., Sirchia R. Type V collagen regulates the expression of apoptotic and stress response genes by breast cancer cells. J Cell Physiol 2005, 202:411-421.
47. Marangoni R.G., Parra E.R., Velosa A.P.P., Teodoro W.R., Capelozzi V.L., Yoshinari N.H. Endothelial dysfunction and abnormal COLV deposition in pulmonary vasculature of experimental systemic sclerosis model (Abstract). Arthritis Rheum 2011, 62(Suppl.):S253.
48. Laplante P., Sirois I., Raymond M.A., Kokta V., Beliveau A., Prat A., et al. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ 2010, 17:291-303.
49. de Oliveira C.C., Velosa A.P.P., Parra E.R., Capelozzi V.L., Teodoro W.R., Yoshinari N.H. Histomorphometric analysis of cutaneous remodeling in the early stage of the scleroderma model. Clinics (Sao Paulo) 2009, 64:577-583.